ALLKGUSD
Allakos Inc.
A clinical-stage biopharmaceutical company developing antibody drugs that target mast cells and eosinophils, the immune cells behind allergic and inflammatory conditions. Its lead experimental medicine, lirentelimab, is being studied for diseases like eosinophilic gastritis and chronic urticaria. Founded in 2012 and based in Redwood City, California, the company's name blends "allergy" with the Greek word "akos," meaning remedy.
CUSIP: 01671P100HealthcareUS1 holder
Total Value
$40.36M
Total Shares
351.6K
Net Share Change
+19.3K
Activity
1 buying
Investor
Value
Shares
Weight
Change
